Breaking News

Par Pharma Appoints Commercial Officer

By Kristin Brooks | February 21, 2014

JHP’s Pera brings more than 30 years of industry experience

Antonio R. Pera has been named chief commercial officer at Par Pharmaceutical Companies. Mr. Pera will lead Par's newly-integrated sales and marketing organization following its acquisition of JHP Pharmaceuticals, and will manage relationships with its major trade partners.
 
Mr. Pera was previously with JHP, where he served as senior vice president, commercial operations. He has more than 30 years of experience in the pharma industry, including manufacturing and wholesale for generic and branded products. Prior to JHP, Mr. Pera was senior vice president, supply chain management at AmerisourceBergen Corp., where he served as a corporate officer and led the procurement function.
 
"Tony has enjoyed a distinguished career in the pharmaceutical industry and we are very pleased to have him join the Par team," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. "He has a demonstrated expertise in the marketing, sales and distribution of generic drugs. We look forward to the leadership Tony will provide our commercial organization and the many contributions he will make to our company."
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments